Latest Safety News

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

King River Resources Ltd (ASX: KRR) has completed its acquisition of the Mindoolah Gold Project in Western Australia’s Murchison Province, unveiling a sophisticated exploration program leveraging digital twin technology and high-resolution geophysics to target substantial unmined high-grade gold mineralisation.

Aurelia Metals reported a strong March quarter with gold production rising to 13koz, upgraded FY26 guidance, and a new A$150 million financing deal that unlocks restricted cash and strengthens liquidity.

Greatland Resources delivered a record $260 million cash build in the March 2026 quarter, underpinned by 82,723 ounces of gold production at a $2,056/oz AISC and a 150% increase in Telfer's Mineral Resource Estimate to 8 million ounces gold.

Predictive Discovery Limited (ASX:PDI) completed its merger with Robex Resources, propelling gold production to 48,178 ounces in Q1 2026 and setting sights on 400,000 ounces annual production by 2029.

TMK Energy’s Gurvantes XXXV project hit a new daily gas production record exceeding 1,350 m³, confirming commercial desorption. The company secured $6 million in funding and regulatory approval to drill three new pilot wells and advance domestic gas use in Mongolia.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.